{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Events+Control&page=2",
    "query": {
      "condition": "Events Control",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Events+Control&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T09:27:26.891Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01327846",
      "title": "Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10066,
      "start_date": "2011-04-11",
      "completion_date": "2019-04-14",
      "has_results": true,
      "last_update_posted_date": "2020-01-22",
      "last_synced_at": "2026-09-04T09:27:26.891Z",
      "location_count": 315,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 248 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01327846"
    },
    {
      "nct_id": "NCT05739383",
      "title": "A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Prevention of Atherosclerotic Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL",
          "type": "DRUG"
        },
        {
          "name": "Placebo in 1.5ml",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "40 Years to 79 Years"
      },
      "enrollment_count": 14012,
      "start_date": "2023-03-09",
      "completion_date": "2029-04-16",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-09-04T09:27:26.891Z",
      "location_count": 242,
      "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 188 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05739383"
    },
    {
      "nct_id": "NCT05771428",
      "title": "Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease (AD)"
      ],
      "interventions": [
        {
          "name": "ABBV-552",
          "type": "DRUG"
        },
        {
          "name": "Placebo for ABBV-552",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 263,
      "start_date": "2023-06-05",
      "completion_date": "2024-09-12",
      "has_results": true,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-09-04T09:27:26.891Z",
      "location_count": 37,
      "location_summary": "Irvine, California • Long Beach, California • Los Alamitos, California + 31 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Clermont",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05771428"
    },
    {
      "nct_id": "NCT04534114",
      "title": "Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "End Stage Renal Disease Requiring Hemodialysis"
      ],
      "interventions": [
        {
          "name": "Fesomersen sodium (BAY2976217)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 307,
      "start_date": "2020-09-04",
      "completion_date": "2022-05-12",
      "has_results": true,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-09-04T09:27:26.891Z",
      "location_count": 9,
      "location_summary": "Clovis, California • Victorville, California • Fort Lauderdale, Florida + 5 more",
      "locations": [
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Victorville",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Saint Ann",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04534114"
    },
    {
      "nct_id": "NCT05463679",
      "title": "Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Vascular Ehlers-Danlos Syndrome"
      ],
      "interventions": [
        {
          "name": "Enzastaurin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aytu BioPharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 260,
      "start_date": "2025-01",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2024-03-08",
      "last_synced_at": "2026-09-04T09:27:26.891Z",
      "location_count": 1,
      "location_summary": "Englewood, Colorado",
      "locations": [
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05463679"
    },
    {
      "nct_id": "NCT03988634",
      "title": "Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure With Preserved Ejection Fraction (HFpEF)"
      ],
      "interventions": [
        {
          "name": "sacubitril/valsartan",
          "type": "DRUG"
        },
        {
          "name": "valsartan",
          "type": "DRUG"
        },
        {
          "name": "sacubitril/valsartan matching placebo",
          "type": "DRUG"
        },
        {
          "name": "valsartan matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 467,
      "start_date": "2019-06-29",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2025-03-06",
      "last_synced_at": "2026-09-04T09:27:26.891Z",
      "location_count": 87,
      "location_summary": "Irvine, California • Long Beach, California • Los Angeles, California + 77 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03988634"
    },
    {
      "nct_id": "NCT07000357",
      "title": "A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "AZD0780",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15100,
      "start_date": "2025-06-04",
      "completion_date": "2029-10-26",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-04T09:27:26.891Z",
      "location_count": 357,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 284 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07000357"
    },
    {
      "nct_id": "NCT00243178",
      "title": "Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Vascular Risk"
      ],
      "interventions": [
        {
          "name": "clopidogrel (SR25990C)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6706,
      "start_date": "2003-07",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2009-10-19",
      "last_synced_at": "2026-09-04T09:27:26.891Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00243178"
    },
    {
      "nct_id": "NCT00187616",
      "title": "Questioning Patients About Adverse Medical Events",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Benign Prostatic Hyperplasia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "50 Years and older · Male only"
      },
      "enrollment_count": 214,
      "start_date": "2002-04",
      "completion_date": "2003-04",
      "has_results": false,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-09-04T09:27:26.891Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00187616"
    },
    {
      "nct_id": "NCT01764633",
      "title": "Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 27564,
      "start_date": "2013-02-08",
      "completion_date": "2016-11-11",
      "has_results": true,
      "last_update_posted_date": "2024-05-28",
      "last_synced_at": "2026-09-04T09:27:26.891Z",
      "location_count": 326,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 275 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01764633"
    }
  ]
}